• Ayşe Karataş, Ümit Yavuz Malkan, Mustafa Velet, Haluk Demiroğlu, Yahya Büyükaşık, Gülçin Telli Dizman, Ahmet Çağkan Inkaya, Batuhan Erdoğdu, Olgu Erkin Çınar, Elifcan Aladağ, Salih Aksu, İbrahim Celalettin Haznedaroğlu, Osman Özcebe, Nilgün Sayınalp, and Hakan Göker.
• Department of Internal Medicine, Division of Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
• Turk J Med Sci. 2021 Aug 30; 51 (4): 1647-1652.

Background/AimThe disease caused by SARS-CoV-2 was named as COVID-19. There is as yet insufficient information about the effects of HSCT on the clinical course of COVID-19. In the present study, we aimed to investigate the clinical course of COVID-19 in patients who had undergone HSCT.Materials And MethodsWe analyzed baseline characteristics, clinical course and findings of COVID-19, hospitalization and death rates, overall survival, and case fatality rates of HSCT recipients diagnosed with COVID-19 retrospectively.Results57.6% of the patients underwent AHSCT, and 42.4% underwent allo-HSCT. 60.6%, 27.3%, and 12.1% of the patients had mild, moderate, and severe COVID-19 or critical illness, respectively. Overall, 45.5% were hospitalized, 12.1% required intensive care, and 9.1% necessitated invasive mechanical ventilation. The total CFR was 9.1% in HSCT recipients, 22.2% in patients with active hematologic malignancy, and 4.2% in patients without active hematologic malignancy.ConclusionIt can be concluded that mortality of HSCT recipients is lower in patients whose primary disease is in remission compared to ones that are not in remission. Further studies with larger group patients are needed in order to delineate the effects of COVID-19 on HSCT patients.This work is licensed under a Creative Commons Attribution 4.0 International License.

23 keywords...

hide…